


CLAIMS**We claim:**

1. A compound of Formula (I):



(I);

or a pharmaceutically acceptable salt thereof, wherein:

R₁ is hydrogen or (C₁-C₆)alkyl;

R₂ is optionally substituted 5-6 membered heteroaryl;


phenyl ring A is optionally substituted; and

R₄ is selected from (C₁-C₆)alkyl, (C₂-C₆)alkenyl, and (C₂-C₆)alkynyl, each of which may be optionally substituted with one or more groups selected from -C(=O)OR^a, -C(=O)NR^aR^b, -C(=O)R^a, -C(=NOR^a)R^b, -C(=NR^a)NR^bR^a, -NR^aC(=O)NR^bR^a, -NR^aC(=O)R^b, -NR^aC(=NR^b)NR^aR^b, -NR^aC(=O)OR^b, -OC(=O)NR^aR^b, -OC(=O)R^a, -OC(=O)OR^a, -S(O)₀₋₃R^a, -SO₂NR^aR^b, -NR^aSO₂R^b, -NR^aSO₂NR^bR^a, and -P(=O)OR^aOR^b, wherein each R^a and R^b are independently hydrogen or (C₁-C₆)alkyl;


provided that the compound of Formula I is not 2-(8-(6-aminopyridin-3-yl)-1-methyl-6-(4-(trifluoromethyl)phenyl)-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, 2-(8-(6-aminopyridin-3-yl)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or 2-(8-(6-aminopyridin-3-yl)-6-(4-fluorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R₄ is selected from -CH₂C(=O)OR^a, -CH₂C(=O)NR^aR^b, and -CH₂C(=O)R^a.


3. The compound of claim 1 or 2, wherein the compound is of Formula (II), (III), or (IV):



(II);



(III); or




(IV);


or a pharmaceutically acceptable salt thereof, wherein phenyl ring A is optionally substituted.

4. The compound of any one of claims 1 to 3, wherein phenyl ring A is optionally substituted with one or more groups represented by R_3 , wherein R_3 is selected from hydrogen, halogen, (C_1-C_6) alkoxy, (C_1-C_6) haloalkoxy, (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, $-CN$, $-NO_2$, $-OH$, $-NR^cR^c$, $-S(O)_iR^c$, $-NR^cS(O)_2R^c$, $-S(O)_2NR^cR^c$, $-C(=O)OR^c$, $-OC(=O)OR^c$, $-C(=S)OR^c$, $-O(C=S)R^c$, $-C(=O)NR^cR^c$, $-NR^cC(=O)R^c$, $-C(=S)NR^cR^c$, $-NR^cC(=S)R^c$, $-NR^c(C=O)OR^c$, $-O(C=O)NR^cR^c$, $-NR^c(C=S)OR^c$, $-O(C=S)NR^cR^c$, $-NR^c(C=O)NR^cR^c$, $-NR^c(C=S)NR^cR^c$, $-C(=S)R^c$, and $-C(=O)R^c$; and wherein each R^c is independently hydrogen or (C_1-C_6) alkyl.


5. The compound of any one of claims 1 to 4, wherein the compound is of Formula (V), (VI), or (VII):



(V);



(VI); or



(VII);

or a pharmaceutically acceptable salt thereof.

6. The compound of any one of claims 1 to 5, wherein R_2 is selected from optionally substituted pyridinyl, optionally substituted pyrazolyl, and optionally substituted oxadiazolyl.

7. The compound of any one of claims 1 to 6, wherein R_2 is selected from pyridinyl, pyrazolyl, and oxadiazolyl, each of which are substituted with one or more groups selected from hydrogen, halogen, (C_1-C_6) alkoxy, (C_1-C_6) haloalkoxy, (C_1-C_6) alkyl, (C_1-C_6) haloalkyl, -CN, $-NO_2$, -OH, $-NR^cR^c$, $-S(O)_2R^c$, $-NR^cS(O)_2R^c$, $-S(O)_2NR^cR^c$, $-C(=O)OR^c$, $-OC(=O)OR^c$, $-C(=S)OR^c$, $-O(C=S)R^c$, $-C(=O)NR^cR^c$, $-NR^cC(=O)R^c$, $-C(=S)NR^cR^c$, $-NR^cC(=S)R^c$, $-NR^c(C=O)OR^c$, $-O(C=O)NR^cR^c$, $-NR^c(C=S)OR^c$, $-O(C=S)NR^cR^c$, $-NR^c(C=O)NR^cR^c$, $-NR^c(C=S)NR^cR^c$, $-C(=S)R^c$, and $-C(=O)R^c$; and wherein each R^c is independently hydrogen or (C_1-C_6) alkyl.


8. The compound of any one of claims 1 to 7, wherein R_1 is alkyl; R_2 is selected from pyridinyl, pyrazolyl, and oxadiazolyl, each of which are substituted with one or more groups

selected from (C₁-C₆)alkoxy, (C₁-C₆)haloalkoxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, halo, hydroxyl, cyano, -NH(C₁-C₆)alkyl, -NH₂, -N(C₁-C₆)alkyl₂, -C(=O)OR^c, -OC(=O)OR^c, and -C(=O)R^c; and R₃ is selected from (C₁-C₆)alkoxy, (C₁-C₆)haloalkoxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, halo, hydroxyl, cyano, -NH(C₁-C₆)alkyl, -NH₂, -N(C₁-C₆)alkyl₂, -C(=O)OR^c, -OC(=O)OR^c, and -C(=O)R^c.

9. The compound of any one of claims 1 to 8, wherein R₁ is methyl; R₂ is selected from pyridinyl, pyrazolyl, and oxadiazolyl, each of which are substituted with one or more groups selected from (C₁-C₆)alkoxy, (C₁-C₆)haloalkoxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, and halo; and R₃ is selected from (C₁-C₆)alkoxy, (C₁-C₆)haloalkoxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, and halo.


10. The compound of any one of claims 1 to 9, wherein R₁ is methyl; R₂ is selected from pyridinyl, pyrazolyl, and oxadiazolyl, each of which are optionally substituted with (C₁-C₆)alkyl; and R₃ is halo.

11. The compound of any one of claims 1 to 10, wherein the compound is of a formula selected from:




or a pharmaceutically acceptable salt thereof.

12. A compound that is of the formula:



or a pharmaceutically acceptable salt thereof.

13. The compound of claim 12, wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the compound in any one of claims 1-13; or a pharmaceutically acceptable salt thereof.

15. A method of treating a human with a disorder modulated by a bromodomain-containing protein, comprising the step of administering to the human an effective amount of the compound in any one of claims 1-13, or a pharmaceutically acceptable salt thereof.

16. The method of claim 15, wherein the disorder is a proliferative disorder, inflammatory disease, sepsis, autoimmune disease, or viral infection.

17. The method of claim 16, wherein the proliferative disorder is a cancer selected from adenocarcinoma, hematological malignancies, adult T-cell leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor.


18. The method of claim 17, wherein the cancer is selected from Burkitt's lymphoma, myelogenous leukemia, hematological malignancies, multiple myeloma, breast cancer, osteosarcoma, ovarian cancer, lung cancer, and colorectal cancer.

19. The method of claim 18, wherein the cancer is acute myelogenous leukemia or Burkitt's lymphoma.

20. The compound of any one of claims 1 to 13, wherein all hydrogen atoms are present at natural abundance.

CLAIMS

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

R_1 is methyl;

R_2 is selected from pyridinyl, pyrazolyl, and oxadiazolyl, each of which are substituted with one or more groups selected from (C₁-C₆)alkoxy, (C₁-C₆)haloalkoxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, and halo;


R_3 is selected from (C₁-C₆)alkoxy, (C₁-C₆)haloalkoxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, and halo;

phenyl ring A is optionally substituted with one or more groups represented by R_3 ; and


R_4 is selected from (C₁-C₆)alkyl, (C₂-C₆)alkenyl, and (C₂-C₆)alkynyl, each of which may be optionally substituted with one or more groups selected from -C(=O)OR^a, -C(=O)NR^aR^b, -C(=O)R^a, -C(=NOR^a)R^b, -C(=NR^a)NR^bR^a, -NR^aC(=O)NR^bR^a, -NR^aC(=O)R^b, -NR^aC(=NR^b)NR^aR^b, -NR^aC(=O)OR^b, -OC(=O)NR^aR^b, -OC(=O)R^a, -OC(=O)OR^a, -S(O)₀₋₃R^a, -SO₂NR^aR^b, -NR^aSO₂R^b, -NR^aSO₂NR^bR^a, and -P(=O)OR^aOR^b, wherein each R^a and R^b are independently hydrogen or (C₁-C₆)alkyl.

2. The compound of claim 1, wherein R_4 is selected from -CH₂C(=O)OR^a, -CH₂C(=O)NR^aR^b, and -CH₂C(=O)R^a.


3. The compound of claim 1 or 2, wherein the compound is of Formula (II), (III), or (IV):



(II);




(III); or




(IV);

or a pharmaceutically acceptable salt thereof, wherein phenyl ring A is optionally substituted with one or more groups represented by R₃.


4. The compound of any one of claims 1 to 3, wherein the compound is of Formula (V), (VI), or (VII):



(V);



(VI); or




(VII);


or a pharmaceutically acceptable salt thereof.

5. The compound of any one of claims 1 to 4, wherein R_1 is methyl; R_2 is selected from pyridinyl, pyrazolyl, and oxadiazolyl, each of which are optionally substituted with (C_1 - C_6)alkyl; and R_3 is halo.


6. The compound of any one of claims 1 to 5, wherein the compound is of a formula selected from:




;



;




; and



;


or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7, wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof.

9. The compound of any one of claims 1 to 8, wherein all hydrogen atoms are present at natural abundance.

10. A pharmaceutical composition comprising: i) a pharmaceutically acceptable carrier or diluent; and ii) the compound in any one of claims 1-9; or a pharmaceutically acceptable salt thereof.